FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Medical experts compare the adverse event profile of lorlatinib to other ALK inhibitors like alectinib and brigatinib, ...

Ensartinib doubled median progression-free survival (PFS) over the first-generation ALK inhibitor, with a median PFS of 25.8 months versus 12.7 months, respectively (HR 0.56, 95% CI 0.40-o.

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

Ensartinib is an ALK tyrosine kinase inhibitor (TKI) designed to improve outcomes for patients with ALK-positive NSCLC. The FDA approval is based on data from the pivotal global Phase III eXalt3 ...

particularly in light of a poster at the Triple Meeting suggesting potent synergy with ALK inhibitors in ALK-positive, resistant NSCLC cell lines. As of their latest quarterly filing, NVCT held $ ...

Dose response curves for cells treated with ALK inhibitors crizotinib and ceritinib (Figure 3 A, B) showed that the isogenic A549 EML4-ALK cell line has selective drug sensitivity to ALK ...

Medical experts discuss approaches to dose modifications and treatment interruptions for adverse events with ALK inhibitors, ...

The company also has NVL-655, an ALK-selective inhibitor for ALK-driven NSCLC. Similar to Zidesamtinib, NLV-655 has brain penetrance, so it should minimize the negative effects on the CNS ...

in TKI pre-treated ALK-positive NSCLC population anticipated by year-end 2025 Report pivotal data for tyrosine kinase inhibitor (TKI) pre-treated patients with advanced ROS1-positive non-small ...

Approval for the new ALK inhibitor was based on findings from the open-label eXalt3 trial, which found patients who received ensartinib had twofold longer progression-free survival compared with ...